Exposure assessment and toxicology interpretation

What supports absolute wording about ozone under every condition a buyer would reasonably infer?

The company's ozone statement is about what the filter gives off, and it rests on the filter having nothing that could generate ozone.

NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The Statement of Classification states at 2.4 that in use the ventilation system's own fan moves air through the filter, that the filter is passive, that it draws no power, and that it has no power supply, electrode, lamp or reservoir, and that it generates no ozone and emits nothing into the air passing through it. The label for the NanoFlashing™ Air Filter states that no power is required and that there is no by-product such as ozone. The polarity is a positive electric charge at rest, and the charge is measured on every production run.

That statement does not extend to ozone already present in the air entering the filter. The company makes no claim about removing ozone from air that already carries it.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.2 and 2.4, issued by NF Technical Products Inc.; NanoFlashing™ Air Filter label.

Reviewed on 21 September 2026.

What information addresses released material or byproducts under foreseeable damage and wear?

The company publishes no release study, no leaching figure and no mass balance.

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

What evidence addresses skin-contact compatibility for the intended garment and wearing conditions?

For skin contact, the company names Product Safety Labs, Study 65323 (skin irritation) and Study 65324 (dermal sensitisation), and OEKO-TEX® Standard 100, Product Class II, Certificate 17.0.25812; it publishes no result for a particular garment under its wearing conditions.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sponsor-supplied sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323, completed 16 February 2024, reported that the material it tested “is classified as non-irritating to the skin”, and Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”; each result describes that sample under that study’s conditions. The Validation page also states that NanoFlashing™ is certified to OEKO-TEX® Standard 100, Product Class II, the class for products in direct contact with skin, and names OEKO-TEX Service GmbH, Certificate 17.0.25812.

Each of those studies describes one endpoint, on that sample, under those conditions. None of them establishes an agency approval, a general safety conclusion, an inhalation result or a health outcome, and irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report. Certificate 17.0.25812 can be checked at source in OEKO-TEX’s public label check.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; OEKO-TEX Label Check, read 19 September 2026, https://www.oeko-tex.com/en/label-check.

Reviewed on 21 September 2026.

Which complete reports address eye and inhalation exposure for the exact finished material and use at issue?

The published record names four health-effects studies, and none of them is an eye study or an inhalation study.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. The page names no study addressing eye exposure and no study addressing inhalation exposure, and the company does not carry a result across to an exposure route a study did not cover.

What it states about what the filter gives off is this. NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 21 September 2026.

What evidence bridges the exposure assessment when a substrate, supplier, process or assembly component changes?

A study covers the article it tested, so a change of substrate, supplier, process or assembly is assessed again by the party that makes the changed article.

The Terms of Use state: “A test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it. Construction, processing, storage, wear, cleaning, other components, and actual use may change the result.” They also state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use,” and: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sponsor-supplied sample. What a complete appliance gives off is a matter for the maker of that appliance, and C-POLAR publishes no assessment of one. A copy may be made available on our review of the request.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/.

Reviewed on 21 September 2026.

Does a safety assessment distinguish the hazard of an ingredient from exposure to the finished article?

The company publishes no hazard assessment of an input and no exposure assessment of a finished article; the four studies it names each cover one endpoint on one submitted sample.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sponsor-supplied sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323, completed 16 February 2024, reported that the material it tested “is classified as non-irritating to the skin”, and Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”; each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. None of them establishes an agency approval, a general safety conclusion, an inhalation result or a health outcome, and irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Can an acute safety result support a claim about repeated long-term exposure?

No, and the company makes no claim about repeated long-term exposure.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the assessment account for cumulative exposure from several products using the same material?

The company publishes no cumulative-exposure estimate.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Are local irritation and systemic toxicity evaluated as different endpoints?

Yes: they are separate studies; Product Safety Labs, Study 65321 (OPPTS 870.1100, acute oral) and Study 65322 (OPPTS 870.1200, acute dermal) are the acute toxicity studies, and Study 65323 (OPPTS 870.2500) is the primary skin irritation study.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sponsor-supplied sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323, completed 16 February 2024, reported that the material it tested “is classified as non-irritating to the skin”, and Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”; each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. None of them establishes an agency approval, a general safety conclusion, an inhalation result or a health outcome, and irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does a negative skin-irritation result address the possibility of sensitisation?

No: skin irritation and sensitisation are separate endpoints, and each has its own study, Product Safety Labs, Study 65323 for skin irritation and Study 65324 for dermal sensitisation.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sponsor-supplied sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323, completed 16 February 2024, reported that the material it tested “is classified as non-irritating to the skin”, and Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”; each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. None of them establishes an agency approval, a general safety conclusion, an inhalation result or a health outcome, and irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Can ingestion evidence be used to support an inhalation claim without a justified bridge?

No: the company does not use its acute oral study, Product Safety Labs, Study 65321, as evidence about inhalation, and none of the four health-effects studies it names is an inhalation study.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. The page names no study addressing eye exposure and no study addressing inhalation exposure, and the company does not carry a result across to an exposure route a study did not cover.

What it states about what the filter gives off is this. NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 21 September 2026.

Does the assessment distinguish fibres, fragments and dissolved substances released from the material?

The company publishes no release study, no leaching figure and no mass balance.

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Are particle-size distributions considered when interpreting inhalation exposure information?

The company publishes no inhalation exposure assessment, so it publishes no particle-size analysis for one; none of the four health-effects studies it names is an inhalation study.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. The page names no study addressing eye exposure and no study addressing inhalation exposure, and the company does not carry a result across to an exposure route a study did not cover.

What it states about what the filter gives off is this. NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 21 September 2026.

Does a safety assessment cover accidental damage as well as intact use?

The company publishes no assessment of a damaged article, and the label directs: “Do not install a filter whose media is torn, crushed, wet or visibly damaged.”

The Terms of Use state: “A test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it. Construction, processing, storage, wear, cleaning, other components, and actual use may change the result.” They also state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use,” and: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sponsor-supplied sample. What a complete appliance gives off is a matter for the maker of that appliance, and C-POLAR publishes no assessment of one. A copy may be made available on our review of the request.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/; NanoFlashing™ Air Filter label.

Reviewed on 21 September 2026.

Can an assessment of an upstream ingredient account for impurities formed during processing?

The company publishes no assessment of an upstream input or of impurities formed in processing, and the property it publishes is a charge, not a substance.

NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. A charge is a physical property. It is not a substance or a mixture of substances. The polarity is a positive electric charge at rest. It is measured as surface charge density, in nanocoulombs per square centimetre. The NanoFlashing manufacturing process produces the charge. The process acts on the filter by physical means. The charge is measured on every production run, and the measurement can be repeated on any filter, upon request.

The company does not publish the composition of the media, and a materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.1, 2.2, 2.3 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Are chronic endpoints excluded explicitly when they have not been evaluated?

The four studies the company names include no chronic endpoint, and the company says so.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the evidence address genotoxic potential where relevant to the intended exposure?

The company publishes no genotoxicity study.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Could an ingredient's degradation products need a different assessment from the original ingredient?

The company publishes no study of degradation products.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Is an estimated exposure based on realistic use frequency and service duration?

The company publishes no exposure estimate based on use frequency or service duration.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the assessment identify uncertainty factors rather than hide them in a safe label?

The company publishes no exposure model, so it states no margin of safety and no uncertainty factor.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines; each study was completed in 2024 on a sponsor-supplied sample. What it names is the record. Each of those studies describes one endpoint on that sample under the conditions it names, and none of them is an exposure assessment. The Terms of Use state: “A reported result describes only what the identified test found.”

An assessment that needs the assumptions behind a calculation is arranged in writing, through [email protected] on the Contact page. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Can an independent assessor inspect the assumptions used to calculate a margin of safety?

The company publishes no exposure model, so it states no margin of safety and no uncertainty factor.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines; each study was completed in 2024 on a sponsor-supplied sample. What it names is the record. Each of those studies describes one endpoint on that sample under the conditions it names, and none of them is an exposure assessment. The Terms of Use state: “A reported result describes only what the identified test found.”

An assessment that needs the assumptions behind a calculation is arranged in writing, through [email protected] on the Contact page. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Does a non-detect for released material state the analytical detection capability?

The company publishes no release study, no leaching figure and no mass balance.

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. That statement is not a measurement of fibres, fragments or dissolved matter. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Can an animal study be interpreted without assuming identical exposure in humans?

An animal study describes the endpoint it measured in that study, and the company does not extend it to people.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does a safety conclusion for adults identify limits on extrapolation to other populations?

The company publishes no extrapolation from one population to another.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Are alternative non-animal evidence sources evaluated for relevance to the actual endpoint?

The company publishes no evaluation of non-animal evidence sources.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Can a supplier distinguish no observed effect from proof that no effect is possible?

Yes: each of the four studies the company names reports its result for one endpoint, on one sample, under that study’s conditions, and none of them is offered as proof that no effect is possible.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sponsor-supplied sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323, completed 16 February 2024, reported that the material it tested “is classified as non-irritating to the skin”, and Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”; each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. None of them establishes an agency approval, a general safety conclusion, an inhalation result or a health outcome, and irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the assessment include emissions from the complete appliance's other components?

C-POLAR publishes no assessment of what the other components of a complete appliance give off; that is a matter for the maker of the appliance.

The Terms of Use state: “A test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it. Construction, processing, storage, wear, cleaning, other components, and actual use may change the result.” They also state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use,” and: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sponsor-supplied sample. A copy may be made available on our review of the request. NanoFlashing™ is a technology; the name, rating and sale of a product that carries it are set by that product's maker and seller.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/.

Reviewed on 21 September 2026.

Does NanoFlashing™ contain silver, copper, zinc or another metal?

C-POLAR describes NanoFlashing™ as a charge, not as a metal or any other substance, and states that the filter contains no active substance.

NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. A charge is a physical property. It is not a substance or a mixture of substances. The company's Statement of Regulatory Status states: “The filter therefore incorporates no substance to act on harmful organisms. It contains no active substance.” The company does not publish the composition of the media.

Source: Statement of Regulatory Status for the NanoFlashing™ Air Filter, sections 2.1 and 3.3, C-POLAR Technologies, Inc., 11 September 2026; C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/.

Reviewed on 21 September 2026.

Does NanoFlashing™ contain or release nanoparticles?

The company states that the filter emits nothing into the air passing through it, and it describes NanoFlashing™ as a charge, not as particles of any size; it publishes no measurement of particles shed from the media.

NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The filter emits nothing into the air passing through it. The air leaving the filter has had nothing added to it. NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. The name is the company's name for the technology. The company does not publish the composition of the media.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.1 and 2.4, issued by NF Technical Products Inc.

Reviewed on 21 September 2026.